Hidradenitis Suppurativa

Latest News

KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study
KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study

November 20th 2023

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.

Secukinumab Demonstrates Efficacy in Reducing Tunnels Associated With Hidradenitis Suppurativa
Secukinumab Demonstrates Efficacy in Reducing Tunnels Associated With Hidradenitis Suppurativa

October 27th 2023

MoonLake Immunotherapeutics Announces 24-Week Data of Sonelokimab for HS
MoonLake Immunotherapeutics Announces 24-Week Data of Sonelokimab for HS

October 16th 2023

Bimekizumab Achieved Meaningful Clinical Improvements in Hidradenitis Suppurativa, According to Data From EADV
Bimekizumab Achieved Meaningful Clinical Improvements in Hidradenitis Suppurativa, According to Data From EADV

October 13th 2023

Stefan Weiss, MD, Discusses OM1’s New HS Dataset and Expanded Dermatology Network
Stefan Weiss, MD, Discusses OM1’s New HS Dataset and Expanded Dermatology Network

October 3rd 2023

Video Interviews
Latest CME Events & Activities

Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices

View More

Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings

View More

Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy

View More

Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients

View More

20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 10, 2024

View More

Facing the Changing Landscape for Neuromodulators and Dermal Fillers

View More

Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis

View More

Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?

View More

"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation

View More

PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa

View More

Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)

View More

Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia

View More

More News

© 2023 MJH Life Sciences

All rights reserved.